Regeneron Pharmaceuticals, Inc. (REGN) Reports 84-Week Pasatru Data Showing Zero New HO Lesions
Regeneron (REGN) reported 84-week data from its Phase 3 OPTIMA extension trial, showing Pasatru had zero new HO lesions vs. 9 on placebo, with a consistent safety profile. The results extend initial 56-week efficacy data. Next catalysts include OPTIMA 2, EU/Japan approvals, and real-world uptake data.
How this was made
The 30-second read
Why it matters
By extending efficacy durability to week 84 with a placebo comparison, the update can reduce perceived risk of waning effect and support continued uptake expectations, though it stops short of new regulatory or commercial guidance.
Market read
Traders may view the week 84 durability signal as incremental positive for Pasatru’s clinical confidence, but without new approvals or financial targets the immediate trading catalyst is likely limited.
What to watch
The piece does not quantify absolute flare-up reduction, statistical significance, or any safety signals beyond “generally consistent,” limiting how far the data can re-rate near-term commercial expectations.
Background
The article frames week 84 OPTIMA extension results as late-stage confirmation extending earlier week 56 efficacy that underpinned FDA approval.
Ticker impact
Regeneron reports OPTIMA extension Phase 3 results from week 56 to 84, showing zero new HO lesions vs 9 on placebo.
Likely supportive bias as traders price in stronger durability and lower flare-up risk versus placebo.
The article discloses additional late-stage efficacy data (week 84) with a clear placebo comparison, but provides no new regulatory decision, guidance, or revenue quantification.
Market effects
Positive late-stage dermatology/ophthalmology-style efficacy durability read-through can lift sentiment for similar chronic inflammatory pipeline programs.
No clear regional market linkage beyond US biotech risk appetite.
Could modestly influence global biotech sentiment around Pasatru’s durability, but no explicit EU/Japan approval decision is reported here.
Counterpoint
Zero new HO lesions may be sensitive to endpoint definitions and follow-up duration; without effect size, subgroup detail, or statistical significance, the market may discount magnitude.
Key entities
- companyRegeneron Pharmaceuticals, Inc.
Reports Phase 3 OPTIMA extension results for Pasatru, including zero new HO lesions at week 84 versus placebo.
